Drug Design of Carbonic Anhydrase Inhibitors.

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Enzymology

Background:

• Carbonic anhydrases (CAs) are zinc metalloenzymes vital for physiological processes.
• Carbonic anhydrase inhibitors (CAIs) are established therapeutics for glaucoma, epilepsy, and increasingly cancer and infections.

Purpose of the Study:

• To provide a comprehensive overview of rational design and synthesis strategies for carbonic anhydrase inhibitors.
• To discuss medicinal chemistry approaches, inhibitor classes, and synthetic methodologies in CAI development.

Main Methods:

• Detailed discussion of the "ring" and "tail" approaches for CAI design.
• Analysis of classical zinc-binding inhibitors (e.g., sulfonamides) and nonclassical inhibitors.
• Evaluation of natural product-derived scaffolds (coumarins, polyamines) and novel chemotypes.

Main Results:

• The "ring" and "tail" approaches offer versatility in optimizing CAI binding affinity and isoform selectivity.
• Nonclassical inhibitors, particularly natural product derivatives, show promise for targeting specific tumor-associated CA isoforms.
• Emerging nonclassical chemotypes require further structural and mechanistic investigation.

Conclusions:

• Rational design of CAIs involves strategic medicinal chemistry approaches to achieve desired therapeutic effects.
• Diverse inhibitor classes, including classical and nonclassical agents, offer a broad spectrum of therapeutic potential.
• Continued research into novel CAIs and their synthetic routes is essential for advancing treatments for various human disorders.